ZLAB250117P2500
- 0.00
- 0.000.00%
Zai Lab Newsroom
Express News | Zai Lab Ltd: Zai Lab Shanghai Entered Into Working Capital Loan Contract With BOCOM Regarding Revolving Credit Facility of up to RMB300 Mln
Insider Sale: See Remarks of $ZLAB (ZLAB) Sells 7,583 Shares
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Zai Lab Announces Director Resignation Amid Board Changes
Zai Lab Ltd Unveils Board of Directors and Leadership
ZAI LAB (09688): Chen Kaixian resigns as Independent Non-Executive Director.
ZAI LAB (09688) announced that Chen Kaixian wishes to resign from the Board of Directors to focus on Other professional and personal matters...
Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The Concept of Innovative Drugs mostly rose, with Shengnuo Pharmaceutical (02257) increasing by 11.56%. Institutions indicate that pharmaceutical innovation is the core driving force of pharmaceutical growth.
Jinwu Finance | Most Innovative Drug Concepts have risen, with Saint Nutra Pharma (02257) up 11.56%, Baiao Saitu (02315) up 9.68%, Geli Pharma (01672) up 7.98%, Lvzhu Bio (02480) up 4.73%, ZAI LAB (09688) up 4.41%, Connaught (02162) up 1.34%, SINO BIOPHARM (01177) up 0.95%, INNOVENT BIO (01801) up 0.69%. Galaxy Securities stated that 1) pharmaceutical innovation is the core driving force of pharmaceutical growth. Innovative drugs have transitioned from Me-too to
Before the Federal Reserve's decision, the rally of U.S. stocks faltered, the Nasdaq said goodbye to record highs, the Dow fell for nine consecutive days, Broadcom dropped over 4%, Chinese concept stocks rebounded against the trend, and Bitcoin reached a
The Dow Jones has seen its first nine consecutive declines since 1978; NVIDIA has seen four consecutive declines, while Tesla has risen over 3% against the trend, hitting new highs for three consecutive days. Chinese concept stocks rebounded nearly 2%, with PDD Holdings rising nearly 3% and Bilibili increasing over 4%. Salaries in the United Kingdom have grown faster than expected, with two-year UK bond yields rising 10 basis points in one day. The USD has rebounded; the Canadian dollar has hit a more than four-year low since the pandemic; Bitcoin surged over $0.108 million during trading, hitting a new historical high for two consecutive days. Crude Oil Product has fallen for two consecutive days, with US oil dropping more than 2% at one point; Gold has hit a new low for the week.
ZAI LAB (09688) issues 8 million shares.
ZAI LAB (09688) announced that on December 17, 2024, the company will issue 8 million new ordinary shares...
Further Weakness as Zai Lab (NASDAQ:ZLAB) Drops 8.9% This Week, Taking Three-year Losses to 61%
Zai Lab Announces Participation in Investor Conference in January 2025
China to Lift Fiscal Spending to Boost Economy
China Central Economic Work Conference: A Key Indicator for Future Market Trends
Tonight, Chinese concepts soared! The nasdaq Golden Dragon index surged by 10%, while fangdd network doubled directly.
Some analysis indicates that the Political Bureau meeting first mentioned stabilizing the stock and real estate markets, and the US stock market quickly rallied on china assets. The 3x Long FTSE china etf surged over 26%, the 2x Long china internet plus-related stocks rose over 22%, the 2x Long FTSE china 50 ETF increased over 17%, and the 2x Long 300etf gained nearly 15%.
China Will Adopt a "Moderately Accommodative" Monetary Policy in the Next Year, The First Shift to Easing Since 2011
Express News | China Signals Major Policy Shift: Hang Seng and Chinese Stocks Rally on Easing Measures
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.